The decrease in viral burden in response to rosiglitazone treatment is in accordance with previous finding by Cloutier et al. The authors have shown that the natural PPARγ agonist (15d-PGJ2) decreased viral titers during influenza infection [49]. Here, PPARG is linked to influenza.